FDG PET Texture Indices As Imaging Biomarkers for Epidermal Growth Factor Receptor Mutation Status in Lung Adenocarcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2023 May 15

PMID 37185611

Authors

Mariko Ishimura

Takashi Norikane

Katsuya Mitamura

Yuka Yamamoto

Yuri Manabe

Mitsumasa Murao

Makiko Murota

Nobuhiro Kanaji

Yoshihiro Nishiyama

Affiliations

Soon will be listed here.

Abstract

Identifying the epidermal growth factor receptor (EGFR) mutation status is important for the optimal treatment of patients with EGFR mutations. We investigated the relationship between F-fluorodeoxyglucose (FDG) positron emission tomography (PET) texture indices and EGFR mutation status in patients with newly diagnosed lung adenocarcinoma. We retrospectively analyzed data of patients with newly diagnosed lung adenocarcinoma who underwent pretreatment FDG PET/computed tomography and EGFR mutation testing between August 2014 and November 2020. Patients were divided into mutated EGFR and wild-type EGFR groups. The maximum standardized uptake value (SUVmax) and 31 texture indices for the primary tumor were calculated from PET images and compared between the two groups. Of the 66 patients included, 22 had mutated EGFR and 44 had wild-type EGFR. The SUVmax did not significantly differ between the two groups. Among the 31 evaluated texture indices, the following five showed a statistically significant difference between the groups: correlation (P = 0.003), gray-level nonuniformity for run (P = 0.042), run length nonuniformity (P = 0.02), coarseness (P = 0.006), and gray-level nonuniformity for zone (P = 0.04). Based on the preliminary results of this study in a small patient population, FDG PET texture indices may be potential imaging biomarkers for the EGFR mutation status in patients with newly diagnosed lung adenocarcinoma.

Citing Articles

Texture Features of F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer.

Norikane T, Ishimura M, Mitamura K, Yamamoto Y, Arai-Okuda H, Manabe Y J Clin Med. 2024; 13(6).

PMID: 38541851 PMC: 10971147. DOI: 10.3390/jcm13061625.

References

Shi A, Wang J, Wang Y, Guo G, Fan C, Liu J . Predictive value of multiple metabolic and heterogeneity parameters of F-FDG PET/CT for EGFR mutations in non-small cell lung cancer. Ann Nucl Med. 2022; 36(4):393-400. DOI: 10.1007/s12149-022-01718-8. View

Zhang J, Zhao X, Zhao Y, Zhang J, Zhang Z, Wang J . Value of pre-therapy F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019; 47(5):1137-1146. DOI: 10.1007/s00259-019-04592-1. View

Zhang M, Bao Y, Rui W, Shangguan C, Liu J, Xu J . Performance of F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer. Front Oncol. 2020; 10:568857. PMC: 7578399. DOI: 10.3389/fonc.2020.568857. View

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View

Orlhac F, Soussan M, Chouahnia K, Martinod E, Buvat I . 18F-FDG PET-Derived Textural Indices Reflect Tissue-Specific Uptake Pattern in Non-Small Cell Lung Cancer. PLoS One. 2015; 10(12):e0145063. PMC: 4682929. DOI: 10.1371/journal.pone.0145063. View

Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A . Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol Cancer. 2019; 18(1):7. PMC: 6325778. DOI: 10.1186/s12943-019-0939-9. View

Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C . LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018; 78(16):4786-4789. DOI: 10.1158/0008-5472.CAN-18-0125. View

Cho A, Hur J, Moon Y, Hong S, Suh Y, Kim Y . Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer. BMC Cancer. 2016; 16:224. PMC: 4793740. DOI: 10.1186/s12885-016-2251-z. View

10.

Huang C, Yen R, Cheng M, Hsu Y, Wei P, Tsai Y . Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol. 2009; 27(1):9-15. DOI: 10.1007/s12032-008-9160-1. View

11.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

12.

Sauter A, Schwenzer N, Divine M, Pichler B, Pfannenberg C . Image-derived biomarkers and multimodal imaging strategies for lung cancer management. Eur J Nucl Med Mol Imaging. 2015; 42(4):634-43. DOI: 10.1007/s00259-014-2974-5. View

13.

Orlhac F, Soussan M, Maisonobe J, Garcia C, Vanderlinden B, Buvat I . Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014; 55(3):414-22. DOI: 10.2967/jnumed.113.129858. View

14.

Caicedo C, Garcia-Velloso M, Dolores Lozano M, Labiano T, Diaz C, Lopez-Picazo J . Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014; 41(11):2058-65. DOI: 10.1007/s00259-014-2833-4. View

15.

Ishimura M, Norikane T, Mitamura K, Yamamoto Y, Arai-Okuda H, Murota M . Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer. Nucl Med Commun. 2021; 43(3):304-309. DOI: 10.1097/MNM.0000000000001517. View

16.

Schillaci O, Urbano N . Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium. Eur J Nucl Med Mol Imaging. 2017; 44(4):563-566. DOI: 10.1007/s00259-017-3616-5. View

17.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

18.

Mak R, Digumarthy S, Muzikansky A, Engelman J, Shepard J, Choi N . Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist. 2011; 16(3):319-26. PMC: 3228101. DOI: 10.1634/theoncologist.2010-0300. View

19.

Yip S, Kim J, Coroller T, Parmar C, Velazquez E, Huynh E . Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer. J Nucl Med. 2016; 58(4):569-576. PMC: 5373502. DOI: 10.2967/jnumed.116.181826. View

20.

Ko K, Hsu H, Huang T, Gao H, Shen D, Chang W . Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur J Nucl Med Mol Imaging. 2014; 41(10):1889-97. DOI: 10.1007/s00259-014-2802-y. View